Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC

Video

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® to detail a phase 2 trial (NCT03173560) of lenvatinib (Lenvima) at 2 starting doses and everolimus to treat patients with renal cell carcinoma, discussing challenges with tolerability of the drugs from a presentation at the 2021 Genitourinary Cancers Symposium.

Transcription:

This particular combination with lenvatinib and everolimus doesn’t include an [immunotherapy] component, it’s just pure targeted therapy. And I would suggest that, in terms of tolerability, it has its challenges. I was hoping that perhaps we could get away with using a lower dose and thereby mitigate some toxicity, but it doesn’t appear that that’s the case. It certainly does suggest to me that perhaps there are challenges as we try to implement the higher dose of lenvatinib with pembrolizumab. [In the CLEAR study (NCT02811861)], they use a dose of 20 mg of lenvatinib, but I can't imagine that that's going to be any easier for patients.

Reference:

Pal SK, Puente J, Heng DYK, et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). Presented at: 2021 Genitourinary Cancers Symposium. Abstract 307.

Recent Videos
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
Related Content